Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes

Trial Profile

Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Dec 2017

At a glance

  • Drugs Insulin aspart (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms ONSET 2
  • Sponsors Novo Nordisk; Novo Nordisk Pharma
  • Most Recent Events

    • 29 Sep 2017 According to a Novo Nordisk media release, the US FDA has approved Fiasp for glycemic control in adults with tyep1 and type 2 diabetes based on data from this and other three trials (231999, 232775, 238002 trials from ONSET programme).
    • 10 Jun 2017 Biomarkers information updated
    • 10 Jan 2017 According to a Novo Nordisk media release, the European Commission has granted marketing authorization for Fiasp for the treatment of diabetes in adults based on data from this and other three trials (231999, 232775, 238002 trials from ONSET programme).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top